Trial
NCT01586195
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Malignant Melanoma
Intervention
Vemurafenib
Why stopped
Recruitment challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-25